Use of NK-1 receptor antagonists for treating cognitive disorders
US6271230A · kind A · utility
4Cited by
15References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 24, 1999 |
| Grant date | Aug 7, 2001 |
| Priority date | — |
| Expiry date | May 24, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/5377
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods for the treatment or prevention of cognitive disorders which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.